Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Lenvatinib in Advanced HCC
NCT03841201Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jun 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03841201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841201.